Imatinib mesylate induces massive and nonspecific aminoaciduria in CML patients

MeSH terms

• Adult
• Aged
• Antineoplastic Agents / adverse effects*
• Antineoplastic Agents / pharmacology
• Antineoplastic Agents / therapeutic use
• Benzamides
• Bone Remodeling / drug effects
• Fanconi Syndrome / chemically induced*
• Fanconi Syndrome / physiopathology
• Female
• Humans
• Hyperparathyroidism, Secondary / blood
• Hyperparathyroidism, Secondary / chemically induced
• Hyperparathyroidism, Secondary / urine
• Hypophosphatemia / chemically induced
• Imatinib Mesylate
• Kidney Tubules, Proximal / drug effects
• Kidney Tubules, Proximal / physiopathology
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive / blood
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive / urine
• Male
• Middle Aged
• Models, Biological
• Piperazines / adverse effects*
• Piperazines / pharmacology
• Piperazines / therapeutic use
• Protein Kinase Inhibitors / adverse effects*
• Protein Kinase Inhibitors / pharmacology
• Protein Kinase Inhibitors / therapeutic use
• Pyrimidines / adverse effects*
• Pyrimidines / pharmacology
• Pyrimidines / therapeutic use
• Remission Induction
• Renal Aminoacidurias / chemically induced*